Advertisement
JOGC

Canadian Contraception Consensus

        This paper is only available as a PDF. To read, Please Download here.

        Abstract

        Objective: To provide guidelines for health-care providers on the use of contraceptive methods to prevent pregnancy and sexually transmitted diseases.
        Outcomes: Overall efficacy of cited contraceptive methods, assessing reduction in pregnancy rate, risk of infection, safety, ease of use, and side effects; the effect of cited contraceptive methods on sexual health and general well-being; and the cost and availability of cited contraceptive methods in Canada.
        Evidence: Medline and the Cochrane Database were searched for articles in English on subjects related to contraception, sexuality, and sexual health from January 1988 to March 2003, in order to update the Report of the Consensus Committee on Contraception published in May-July 1998. Relevant Canadian Government publications and position papers from appropriate health and family planning organizations were also reviewed.
        Values: The quality of the evidence is rated using the criteria described in the Report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this Report.

        Key Words

        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic and Personal
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'

        Subscribe:

        Subscribe to Journal of Obstetrics and Gynaecology Canada
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect

        References

          • Wilkins K
          • Johansen H
          • Beaudet MP
          • Neutel CI
          Oral contraceptive use. 2000; 11 (Statistics Canada. Health Reports): 25-37
        1. Fisher W, Boroditsky R, Morris B. The 2002 Canadian Contraception Study. J Obstet Gynaecol Can 2003. (in Press)

          • Upton GC
          The phasic approach to oral contraception: the triphasic concept and its application.
          Int J Fertil. 1983; 28: 121-140
          • Fotherby K
          Bioavailablity of orally administered sex steroids used in oral contraceptives and hormone replacement therapy.
          Contraception. 1996; 544: 59-69
          • Dickey RR
          Managing contraceptive pill patients.
          8th ed. Emis Medical Publishers, Dallas1994
          • Weems Chihal HL
          • Peppier RD
          • Dickey RR
          Estrogen potency of oral contraceptive pills.
          Am J Obstet Gynecol. 2003; 121: 75-83
          • Kühl H
          Comparative pharmacology of newer progestins.
          Drugs. 1996; 51: 188-215
          • Fotherby K
          • Caldwell AD
          New progestins in oral contraception.
          Contraception. 1994; 49: 1-32
          • World Health Organization
          Improving access to quality care in family planning: medical eligibility criteria for contraceptive use.
          2nd ed. WHO, Geneva2001
          • Hatcher RA
          • Trussell J
          • Stewart F
          • Cates W
          • Stewart G K
          • Guest F
          • et al.
          Contraceptive Technology.
          17th ed. Ardent Media Inc, New York1998
          • Fu H
          • Darroch JE
          • Haas T
          • Ranjit N
          Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth.
          Farn Plann Perspect. 1999; 31: 56-63
          • Potter L
          • Oakley D
          • de Leon-Wong E
          • Canamar R
          Measuring compliance among oral contraceptive users.
          Farn Plann Perspect. 1996; 28: 154-158
          • Waugh Rosenberg MJ
          • MS Burnhill MS
          Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation.
          Farn Plann Perspect. 1998; 30: 89-92
          • Holt VL
          • Cushing-Haugen KL
          • Daling JR
          Body weight and risk of oral contraceptive failure.
          Obstet Gynecol. 2002; 99: 820-827
          • Vessey M
          Oral contraceptive failures and body weight findings in a large cohort study.
          J Farn Plann Reprod Health Care. 2001; 27: 90-91
          • Diczfalusy E
          Probable mode of action of oral contraceptives.
          Res Steroids. 1966; 2: 389-392
          • Mitra PK
          • Roychadhuri J
          Effect of oral contraceptives on the ultrastructure of the endometrium.
          J Gynaecol Endocrinol. 1987; 3: 13-15
          • Rossmanith WG
          • Steffens D
          • Schramm G
          A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
          Contraception. 1997; 56: 23-30
          • Larsson G
          • Milsom I
          • Lindstedt G
          • Rybo G
          The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status.
          Contraception. 1992; 46: 327-334
          • Iyer V
          • Farquhar C
          • Jepson R
          Oral contraceptive pills for heavy menstrual bleeding (Cochrane Methodology Review).
          in: The Cochrane Database of Systematic Reviews. 2003 (Issue 4)
          • Berenson AB
          • Radecki C
          • Grady JJ
          • et al.
          A prospective, controlled study of the effects of hormonal contraception on bone mineral density.
          Obstet Gynecol. 2001; 98: 576-582
          • Petitti DB
          • Piaggio G
          • Mehta S
          • Cravioto MC
          • Meirik O
          Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health.
          Obstet Gynecol. 2000; 95: 736-744
          • Gambacciani M
          • Spinetti A
          • Taponeco F
          • Cappagli B
          • Piaggesi L
          • Fioretti P
          Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism.
          Obstet Gynecol. 1994; 83: 392-396
          • Kritz-Silverstein D
          • Barrett-Connor E
          Bone mineral density in postmenopausal women as determined by prior oral contraceptive use.
          Am J Public Health. 1993; 83: 100-102
          • Hendrix SL
          • Alexander NJ
          Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive.
          Contraception. 2002; 66: 393-399
          • Milsom I
          • Sundell G
          • Andrersch B
          The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea.
          Contraception. 1990; 42: 497-506
          • Sundell G
          • Milsom I
          • Andersch B
          Factors influencing the prevalence and severity of dysmenorrhoea in young women.
          Br J Obstet Gynaecol. 1990; 97: 588-594
          • Casper RF
          • Dodin S
          • Reid RL
          The effect of 20mcg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women.
          Menopause. 1997; 4: 139-147
          • Shargril AA
          Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three year prospective study.
          Int J Fertility. 1985; 30: 18-28
          • Redmond GP
          • Olson WH
          • Lippman JS
          • Kafrissen ME
          • Jones TM
          • Jorizzo JL
          Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
          Obstet Gynecol. 1997; 89: 615-622
          • Lemay A
          • Poulin Y
          Oral contraceptives as anti-androgenic treatment of acne.
          J Obstet Gynaecol Can. 2002; 24: 559-567
          • Thiboutot D
          • Archer DF
          • Lemay A
          • Washenik K
          • Roberts J
          • Harrison DD
          A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment.
          Fertil Steril. 2001; 76: 461-468
          • Lucky AW
          • Henderson TA
          • Olson WH
          • Robisch DM
          • Lebwohl M
          • Swinyer LJ
          Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
          J Am Acad Dermatol. 1997; 37: 746-754
          • Thorneycroft IH
          • Stanczyk FZ
          • Bradshaw KD
          • Ballagh SA
          • Nichols M
          • Weber ME
          Effect of low-dose oral contraceptives on androgenic markers and acne.
          Contraception. 1999; 60: 255-262
          • Mango D
          • Ricci S
          • Manna P
          • et al.
          Clinical and hormonal effects of ethinyl estradiol combined with gestodene and desogestrel in young women with acne vulgaris.
          Contraception. 1996; 53: 163-170
          • Carlborg L
          Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne: results of a multicenter study.
          Acta Obstet Gynecol Scand Suppl. 1986; 134: 29-32
          • Dewis D
          • Petsos M
          • Anderson DC
          The treatment of hirsutism with a combination of desogestrel and ethinyl estradiol.
          Clin Endocrin. 1985; 22: 29-36
          • Centers for Disease Control and Prevention
          Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.
          JAMA. 1983; 257: 796-800
          • Collins JA
          • Schlesselman JJ
          Perimenopausal use of reproductive hormones effects on breast and endometrial cancer.
          Obstet Gynecol Clin North Am. 2002; 29: 511-525
          • Schlesselman JJ
          Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner’s guide to meta-analysis.
          Hum Reprod. 1997; 12: 1851-1863
          • Schlesselman JJ
          Net effect of oral contraceptive use on the risk of cancer in women in the United States.
          Obstet Gynecol. 1995; 85: 793-801
          • Sherman ME
          • Sturgeon S
          • Brinton LA
          • Potischman N
          • Kurman RJ
          • Berman ML
          • et al.
          Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
          Mod Pathol. 1997; 10: 963-968
          • Bosetti C
          • Negri E
          • Trichopoulos D
          • Franceschi S
          • Beral V
          • Tzonou A
          • et al.
          Long-term effects of oral contraceptives on ovarian cancer risk.
          Int J Cancer. 2002; 102: 262-265
          • Gross TP
          • Schlesselman JJ
          The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer.
          Obstet Gynecol. 2003; 83: 419-424
          • Hankinson SE
          • Colditz GA
          • Hunter DJ
          • Spencer TL
          • Rosner B
          • Stampfer MJ
          A quantitative assessment of oral contraceptive use and ovarian cancer.
          Obstet Gynecol. 1992; 80: 708-714
          • Ness RB
          • Grisso JA
          • Klapper J
          • Schlesselman JJ
          • Silberzweig S
          • Vergona R
          • et al.
          Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions.
          Am J Epidemiol. 2000; 152: 233-241
          • Walker GR
          • Schlesselman JJ
          • Ness RB
          Family history of cancer, oral contraceptive use, and ovarian cancer risk.
          Am J Obstet Gynecol. 2003; 186: 8-14
          • Narod SA
          • Risch H
          • Moslehi R
          • Dorum A
          • Neuhausen S
          • Olsson H
          • et al.
          Oral contraceptives and the risk of hereditary ovarian cancer.
          N Engl J Med. 1998; 339: 424-428
          • Ross RK
          • Pike MCVessey MP
          • Bull D
          • Yeates D
          • Casagrande JT
          Risk factors for uterine fibroids: reduced risk associated with oral contraceptives.
          BMJ. 1986; 293: 359-362
          • Chiaffarino F
          • Parazzini F
          • La Vecchia C
          • Marsico S
          • Surace M
          • Ricci E
          Use of oral contraceptives and uterine fibroids: results from a case-control study.
          Br J Obstet Gynaecol. 1999; 106: 857-860
          • Lanes SF
          • Birmann B
          • Walker AM
          • Singer S
          Oral contraceptive type and functional ovarian cysts.
          Am J Obstet Gynecol. 1992; 166: 956-961
          • Brinton LA
          • Vessey MP
          • Flavel R
          • Yeates D
          Risk factors for benign breast disease.
          Am J Epidemiol. 1981; 113: 203-214
          • Martinez ME
          • Grodstein F
          • Giovannucci E
          • Colditz GA
          • Speizer FE
          • Hennekens C
          • et al.
          A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer.
          Cancer Epidemiol Biomarkers Prev. 1997; 6: 1-5
          • Fernandez E
          • La Vecchia C
          • Franceschi S
          • Braga C
          • Talamini R
          • Negri E
          • et al.
          Oral contraceptive use and risk of colorectal cancer.
          Epidemiology. 1998; 9: 295-300
          • Franceschi S
          • La Vecchia C
          Oral contraceptives and colorectal tumors: a review of epidemiologic studies.
          Contraception. 1998; 58: 335-343
          • Washington Cates W
          • AE Peterson HB
          The pill, chlamydia and PID.
          Farn Plann Perspect. 1985; 17: 175-176
          • La Panser
          • Phipps WR
          Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease.
          Contraception. 1991; 43: 91-99
          • Walker A
          • Bancroft J
          Relationship between premenstrual symptoms and oral contraceptive use: a controlled study.
          Psychosom Med. 1990; 52: 86-96
          • Rosenberg MJ
          • Meyers A
          • Roy V
          Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations.
          Contraception. 1999; 60: 321-329
          • Rosenberg MJ
          • Waugh MS
          Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.
          Am J Obstet Gynecol. 1998; 179: 577-582
          • The ESHRE Capri Workshop Group
          Continuation rates for oral contraceptives and hormone replacement therapy.
          Hum Reprod. 2000; 15: 1865-1871
          • Thorneycroft I
          Cycle control with oral contraceptives: a review of the literature.
          Am J Obstet Gynecol. 1999; 180: 280-287
          • Casper RF
          • Powell AM
          Evaluation and therapy of breakthrough bleeding in women using a triphasic oral contraceptive.
          Fertil Steril. 1991; 55: 292-296
          • Saleh WA
          • Burkman RT
          • Zacur HA
          • Kimball AW
          • Kwiterovich P
          • Bell WK
          A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
          Am J Obstet Gynecol. 1993; 168: 1745-1747
          • Ansbacher R
          Low-dose oral contraceptives: health consequences of discontinuation.
          Contraception. 2000; 62: 285-288
          • Clark LR
          Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls.
          J Ped Adolesc Gynecol. 2001; 14: 153-162
          • Borgelt-Hansen L
          Oral contraceptives: an update on health benefits and risks.
          J Am Pharm Assoc. 2001; 41: 875-886
          • Endrikat J
          • Dusterberg B
          • Ruebig A
          • Gerlinger C
          • Strowitzki T
          Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
          Contraception. 1999; 60: 269-274
          • Halbe HW
          • de Melo NR
          • Bahamondes L
          • Petracco A
          • Lemgruber M
          • de Andrade RR
          • et al.
          Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
          Eur J Contracept Reprod Health Care. 1998; 3: 113-120
          • Archer DF
          • Maheux R
          • Delconte A
          • O’Brien FB
          Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse).
          Am J Obstet Gynecol. 1999; 181: 39-44
          • Zichella L
          • Sbrignadello QTomassini A
          • Di Lieto A
          • Montoneri C
          • Zarbo G
          • et al.
          Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
          Adv Contracept. 1999; 15: 191-200
          • Fisher WA
          • Boroditsky R
          • Bridges ML
          The 1998 Canadian Contraception Study.
          Can J Human Sexuality. 1999; 8: 161-216
          • Redmond G
          • Godwin AJ
          • Olson W
          • Lippman JS
          Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence.
          Contraception. 1999; 60: 81-85
          • Coney R
          • Washenik K
          • Langley RGB
          • DiGiovanna JJ
          • Harrison DD
          Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.
          Contraception. 2001; 63: 297-302
          • Gupta S
          Weight gain on the combined pill: is it real?.
          Hum Reprod Update. 2000; 6: 427-431
          • Endrikat J
          • Hite R
          • Bannemerschult R
          • Gerlinger C
          • Schmidt W
          Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
          Contraception. 2001; 64: 3-10
          • Vandenbroucke JR
          • Rosing J
          • Bloemenkamp KW
          • Middeldorp S
          • Heimerhorst FM
          • Bouma BN
          • et al.
          Oral contraceptives and the risk of venous thrombosis.
          N Engl J Med. 2001; 344: 1527-1535
          • Lidegaard O
          • Edstrom B
          • Kreiner S
          Oral contraceptives and venous thromboembolism: a five-year national case-control study.
          Contraception. 2002; 65: 187-196
          • Lidegaard O
          • Edstrom B
          • Kreiner S
          Oral contraceptives and venous thromboembolism: a case-control study.
          Contraception. 1998; 57: 29l-30l
          • Farley TM
          • Collins J
          • Schlesselman JJ
          Hormonal contraception and risk of cardiovascular disease: an international perspective.
          Contraception. 1998; 57: 211-230
          • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study.
          Lancet. 1997; 349: 1202-1209
          • Sidney S
          • Siscovick DS
          • Petitti DB
          • Schwartz SM
          • Quesenberry CR
          • Psaty BM
          • et al.
          Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies.
          Circulation. 1998; 98: 1058-1063
          • Sidney S
          • Petitti DB
          • Quesenberry Jr, CP
          • Klatsky AL
          • et al.
          Myocardial infarction in users of low-dose oral contraceptives.
          Obstet Gynecol. 1996; 88: 939-944
          • Rosenberg L
          • Palmer JR
          • Rao RS
          • Shapiro S
          Low-dose oral contraceptive use and the risk of myocardial infarction.
          Arch Intern Med. 2001; 161: 1065-1070
          • Dunn N
          • Thorogood M
          • Faragher B
          • de Caestecker L
          • MacDonald TM
          • McCollum C
          • et al.
          Oral contraceptives and myocardial infarction: results of the MICA case-control study.
          BMJ. 1999; 318: 1579-1583
          • Poulter NR
          Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
          Lancet. 1996; 348: 498-505
          • Schwartz SM
          • Petitti DB
          • Siscovick DS
          • Longstreth Jr, WT
          • Sidney S
          • Raghunathan TE
          • et al.
          Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies.
          Stroke. 1998; 29: 2277-2284
          • Petitti DB
          • Sidney S
          • Bernstein A
          • Wolf S
          Stroke in users of low-dose oral contraceptives.
          N Engl J Med. 1996; 335: 8-15
          • Lidegaard O
          • Kreiner S
          Contraceptives and cerebral thrombosis: a five-year national case-control study.
          Contraception. 2002; 65: 197-205
          • Lidegaard O
          Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
          BMJ. 1993; 306: 956-963
          • Heinemann LA
          • Lewis MA
          • Spitzer WO
          • Thorogood M
          • Guggenmoos-Holzmann I
          • et al.
          Thromboembolic stroke in young women: a European case-control study on oral contraceptives.
          Contraception. 1998; 57: 29-37
          • Kemmeren JM
          • Tanis BC
          • van den Bosch MA
          • Bollen EL
          • Heimerhorst FM
          • van der Graaf Y
          • et al.
          A. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.
          Stroke. 2002; 33: 1202-1208
          • Goldstein LB
          • Adams R
          • Becker K
          • Furberg CD
          • Gorelick PB
          • Hademenos G
          • et al.
          Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association.
          Stroke. 2001; 32: 280-299
          • Curtis KM
          • Chrisman CE
          • Peterson HB
          Contraception for women in selected circumstances.
          Obstet Gynecol. 2002; 99: 1100-1112
          • Gillum LA
          • Mamidipudi SK
          • Johnston SC
          Ischemic stroke risk with oral contraceptives: a meta-analysis.
          JAMA. 2000; 284: 72-78
          • Bennion LJ
          • Ginsberg RL
          • Gernick MB
          • Bennett PH
          Effects of oral contraceptives on the gallbladder bile of normal women.
          N Engl J Med. 1976; 294: 189-192
        2. Benign gallbladder disease: newer data suggest little or no excess risk with oral contraceptive use. Contracept Rep 1997; 8(5): 9-11.

          • Grodstein F
          • Colditz GA
          • Hunter DJ
          • Manson JE
          WillettWC, Stampfer MJ. A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors.
          Obstet Gynecol. 1994; 84: 207-214
          • Oral-contraceptive use and the risk of breast cancer
          The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.
          N Engl J Med. 1986; 315: 405-411
        3. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347(9017): 1713-27.

          • Bryant HE
          • Brasher PM
          Risks and probabilities of breast cancer: short-term versus lifetime probabilities.
          CMAJ. 1994; 150: 211-216
          • Marchbanks PA
          • McDonald JA
          • Wilson HG
          • Folger SG
          • Mandel MG
          • Dating JR
          • et al.
          Oral contraceptives and the risk of breast cancer.
          N Engl J Med. 2002; 346: 2025-2032
          • Narod SA
          • Dube MP
          • Klijn J
          • Lubinski J
          • Lynch HT
          • Ghadirian P
          • et al.
          Oral contraceptives and the risk of breast cancer in BRCAI and BRCA2 mutation carriers.
          J Nad Cancer Inst. 2002; 94: 1773-1779
          • Ursin G
          • Henderson BE
          • Haile RW
          • et al.
          Does oral contraceptive use increase the risk of breast cancer in women with BRCAI/BRCA2 mutations more than in other women?.
          Cancer Res. 1997; 57: 3678-3681
          • Heimdal K
          • Skovlund E
          • Moller R
          Oral contraceptives and risk of familial breast cancer.
          Cancer Detect Prev. 2002; 26: 23-27
          • Moreno V
          • Bosch FX
          • Munoz N
          • Meijer CJ
          • Shah KV
          • Walboomers JM
          • et al.
          International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.
          Lancet. 2002; 359: 1085-1092
          • Smith JS
          • Green J
          • Berrington de Gonzalez A
          • Appleby P
          • Peto J
          • Plummer M
          • et al.
          Cervical cancer and use of hormonal contraceptives: a systematic review.
          Lancet. 2003; 361: 1159-1167
          • Franco EL
          • Duarte-Franco E
          • Ferenczy A
          Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.
          CMAJ. 2001; 164: 1017-1025
          • Castle PE
          • Wacholder S
          • Lorincz AT
          • Scott DR
          • Sherman ME
          • Glass AG
          • et al.
          A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.
          J Natl Cancer Inst. 2002; 94: 1406-1414
          • Royar J
          • Becher H
          • Chang-Claude J
          Low-dose oral contraceptives: protective effect on ovarian cancer risk.
          Int J Cancer. 2001; 95: 370-374
          • Modan B
          • Hartge P
          • Hirsh-Yechezkel G
          • Chetrit A
          • Lubin F
          • Bélier U
          • et al.
          Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCAI or BRCA2 mutation.
          N Engl J Med. 2001; 345: 235-240
          • Shulman LP
          Oral contraceptives: risks.
          Obstet Gynecol Clin N Am. 2000; 27: 695-704
          • Hatcher RA
          • Guillebaud MA
          The pill: combined oral contraceptives.
          in: Hatcher RA Trussell J Stewart F Cates Jr., W Stewart GK Guest F Contraceptive technology. Ardent Media, New York1998: 405-466
        4. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

          • van derVange N
          • Blankenstein MA
          • Kloosterboer HJ
          • Haspels AA
          • Thijssen JH
          Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone.
          Contraception. 1990; 41: 345-352
          • Lara-Torre E
          • Schroeder B
          Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills.
          Contraception. 2002; 66: 81-85
          • Westhoff C
          • Kerns J
          • Morroni C
          • Cushman LF
          • Tiezzi L
          • Murphy PA
          Quick Start a novel oral contraceptive initiation method.
          Contraception. 2002; 66: 141-145
          • Westhoff C
          • Morroni C
          • Kerns J
          • Murphy PA
          Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial.
          Fertil Steril. 2003; 79: 322-329
          • Loudon N
          • Foxwell M
          • Potts D
          • Guild A
          • Short R
          Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen.
          BMJ. 1977; 2: 487-490
          • Sulak P
          • Kueh IT
          • Ortiz M
          • Shull B
          Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormonal withdraw symptoms.
          Am J Obstet Gynecol. 2002; 186: 1142-1149
          • Vercellini P
          • De Giorgi O
          • Mosconi R Stellato G
          • Vicentini S
          • Crosignani PG
          Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis.
          Fertil Steril. 2002; 77: 52-61
          • Falsetti L
          • Galbignani E
          Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
          Contraception. 1990; 42: 611-619
          • Grimes D
          The safety of oral contraceptives: epidemiologic insights from the first 30 years.
          Am J Obstet Gynecol. 1992; 166: 1950-1954
          • Miller L
          • Hughes JR
          Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial.
          Obstet Gynecol. 2003; 101: 653-661
          • Anderson FD
          • Hait H
          A multicenter, randomized study of an extended cycle oral contraceptive.
          Contraception. 2003; 68: 89-96
          • Rutter W
          • Knight C
          • Vizzard J
          • Mira M
          • Abraham S
          Women’s attitudes to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pill.
          Med J Aust. 1988; 149: 417-419
          • Tonkelaar den
          • Oddens B
          Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use.
          Contraception. 1999; 59: 357-362
          • Cachrimanidou AC
          • Hellberg D
          • Nilsson S
          • Waldenstrom U
          • Olsson SE
          • Sikstrom B
          Long-interval treatment regimen with a desogestrel-containing oral contraceptive.
          Contraception. 1993; 48: 205-216
          • Hamerlynck J
          • Vollebregt J
          • Doomebos C
          • Muntendam P
          Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
          Contraception. 1987; 35: 199-205
          • Ziaei S
          • Rajaei L
          • Faghihzadeh S
          • Lamyian M
          Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route.
          Contraception. 2002; 65: 329-331
          • Coutinho EM
          • Mascarenhas I
          • de Acosta OM
          • Flores JG
          • Gu ZP
          • Ladipo OA
          • et al.
          Comparative study on the efficacy, acceptability, and side effects of a contraceptive pill administered by the oral and the vaginal route: an international multicenter clinical trial.
          Clin Pharmacol Ther. 1993; 54: 540-545
          • Coutinho EM
          • de Souza JC
          • da Silva AR
          • de Acosta OM
          • Alvarez F
          • Brache V
          • et al.
          Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
          Clin Pharmacol Ther. 1993; 53: 65-75
          • Coutinho EM
          • O’Dwyer E
          • Barbosa IC
          • Gu ZP
          • Shaaban MM
          • Aboul-Oyoon M
          • et al.
          Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route.
          Contraception. 1995; 516: 355-358
          • Souka AR
          • el Sokkary H
          • Hassan M
          The effect of vaginal administration of low-dose oral contraceptive tablets on human ovulation.
          Contraception. 1986; 33: 365-371
          • Coutinho EM
          • da Silva AR
          • Carreira C
          • Rodrigues V
          • Goncalves MT
          Conception control by vaginal administration of pills containing ethinyl estradiol and dl-norgestrel.
          Fertil Steril. 1984; 42: 478-481
          • Coutinho EM
          • Silva AR
          • Carreira C
          • Barbosa I
          Ovulation inhibition following vaginal administration of pills containing norethindrone and mes-tranol.
          Contraception. 1984; 29: 197-202
          • Schilling LH
          • Bolding OT
          • Chenault CB
          • Chong AP
          • Fleury F
          • Forrest K
          • et al.
          Evaluation of the clinical performance of the triphasic oral contraceptives: a multicenter, randomized, comparative trial.
          Am J Obstet Gynecol. 1989; 160: 1264-1268
          • Audet MC
          • Moreau M
          • Koltun WD
          • Waldbaum AS
          • Shangold G
          • Fisher AC
          • et al.
          ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptives randomized controlled trial.
          JAMA. 2001; 285: 2347-2354
          • Rosenberg MJ
          • Waugh MS
          • Higgens JE
          The effect of desogestrel. gestodene, and other factors on spotting and bleeding.
          Contraception. 1996; 53: 85-90
          • Rosenberg MJ
          • Waugh MS
          Smoking and cycle control among oral contraceptive users.
          Am J Obstet Gynecol. 1996; 174: 628-632
          • Krettek JE
          • Arkin SI
          • Chaisilwattana P
          • Monif GR
          Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting.
          Obstet Gynecol. 1993; 81: 728-731
          • Rosenberg MJ
          • Meyers A
          • Roy V
          Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 [mu]g and 35 [mu]g estrogen preparations.
          Contraception. 1999; 60: 321-329
          • Bracken MB
          Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies.
          Obstet Gynecol. 1990; 76: 552-557
          • D’Arcy PF
          Drug interactions with oral contraceptives.
          Drug Intell Clin Pharm. 1986; 20: 353-362
          • Fotherby K
          Interactions with oral contraceptives.
          Am J Obstet Gynecol. 1990; 163: 2153-2159
          • Oesterheld JR
          Gynecology: oral contraceptives.
          in: Cozza KL Armstrong SC The cytochrome P450 system drug interaction principles for medical practice. American Psychiatric Publishing Inc, Washington DC2001: 103-114
          • Crawford P
          • Chadwick DJ
          • Martin C
          • Tjia J
          • Back DJ
          • Orme M
          The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.
          Br J Clin Pharmacol. 1990; 30: 892-896
          • Dickinson BD
          • Altman RD
          • Nielsen H
          • Sterling ML
          Drug interactions between oral contraceptives and antibiotics.
          Am J Obstet Gynecol. 2001; 98: 853-860
          • Hachad H
          • Ragueneau-Majlessi I
          • Levy RH
          New antiepileptic drugs: review on drug interactions.
          Ther Drug Monit. 2002; 24: 91-103
          • Schwarz UI
          • Buschel B
          • Kirch W
          Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception.
          Br J Clin Pharmacol. 2003; 55: 112-113
          • Abrams LS
          • Skee DM
          • Natarajan J
          • Wong FA
          Pharmacokinetic overview of Ortho Evra/Evra.
          Fertil Steril. 2002; 77: S3-S12
          • Smalrwood GH
          • Meador ML
          • Lenihan JP
          • Shangold GA
          • Fisher AC
          • Creasy GW
          ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system.
          Obstet Gynecol. 2001; 98: 799-805
          • Zieman M
          • Guillebaud J
          • Weisberg E
          • Shangold G
          • Fisher AC
          • Creasy GW
          Contraceptive efficacy and cycle control with Ortho Evra/Evra transdermal system: the analysis of pooled data.
          Fertil Steril. 2002; 77: S13-S18
          • Gu S
          • Sivin I
          • Du M
          • Zhang L
          • et al.
          Effectiveness of Norplant implants through seven years: a large-scale study in China.
          Contraception. 2003; 52: 99-103
          • Pierson RA
          • Archer DF
          • Moreau M
          • Shangold GA
          • Fisher AC
          • Creasy GW
          Ortho Evra™/Evra™/ versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
          Fertil Steril. 2003; 80: 34-42
          • Sibai BM
          • Odlind V
          • Neador ML
          • Shangold G
          • Fisher AC
          • Creasy GW
          A comparative and pooled analysis of the safety and tolerability of the contraceptive patch.
          Fertil Steril. 2002; 77: S19-S26
          • Zacur HA
          • Hedon B
          • Mansour D
          • Shangold G
          • Fisher AC
          Integrated summary of ortho evra/evra contraceptive patch adhesion in varied climates and conditions.
          Fertil Steril. 2002; 77: S32-S35
          • Gallo MF
          • Grimes DA
          • Schulz KF
          • Heimerhorst FM
          Combination contraceptives: effects on weight (Cochrane Review).
          in: The Cochrane Library. Update Software, Oxford2003 (Issue 4)
          • Abrams LS
          • Skee DM
          • Natarajan J
          • Wong FA
          • Anderson GD
          Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelge-stromin and ethinyloestradiol at four application sites.
          Br J Clin Pharmacol. 2002; 53: 141-146
          • Abrams LS
          • Skee DM
          • Wong FA
          • Anderson NJ
          • Leese PT
          Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
          J Clin Pharmacol. 2001; 41: 1232-1237
          • Timmer CJ
          • Mulders TM
          Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
          Clin Pharmacokinet. 2000; 39: 233-242
          • Roumen FJ
          • Apter D
          • Mulders TM
          • Dieben TO
          Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.
          Hum Reprod. 2001; 16: 469-475
          • Dieben TO
          • Roumen FJ
          • Apter D
          Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.
          Obstet Gynecol. 2002; 100: 585-593
          • Mulders TM
          • Dieben TO
          Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
          Fertil Steril. 2001; 75: 865-870
          • Mulders TM
          • Dieben TO
          • Bennink HJ
          Ovarian function with a novel combined contraceptive vaginal ring.
          Hum Reprod. 2002; 17: 2594-2599
          • Killick S
          Complete and robust ovulation inhibition with NuvaRing.
          Eur J Contracept Reprod Health Care. 2002; 7: 13-18
          • Bjarnadottir RI
          • Tuppurainen M
          • Killick SR
          Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel /ethinyl estradiol.
          Am J Obstet Gynecol. 2002; 186: 389-395
          • Alexander NJ
          • Haring T
          • Mulders TM
          A pharmacokinetic interaction study of NuvaRing and a vaginally administered spermicide or antimy-cotic [abstract 0-63].
          Fertil Steril. 2002; 78: S24-25
          • Kaunitz AM
          • Garceau RJ
          • Cromie MA
          Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic).
          Contraception. 1999; 60: 179-187
          • Rahimy MH
          • Ryan KK
          Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
          Contraception. 1999; 60: 189-200
          • Wajszczuk Garceau RJ
          • CJ Kaunitz AM
          Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives.
          Contraception. 2002; 62: 289-295
          • Jain JK
          • Ota F
          • Mishell DR
          Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive.
          Contraception. 2000; 61: 195-198
          • Kaunitz AM
          • Garceau RJ
          • Cromie MA
          Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group.
          Contraception. 1999; 60: 179-187

        References

        1. Fisher W, Boroditsky R, Morris B. The 2002 Canadian contraception study. J Obstet Gyneacol Can 2003. In press.

          • Hatcher RA
          • Trussell J
          • Stewart F
          • Cates W
          • Stewart GK
          • Guest F
          • et al.
          Contraceptive technology.
          17th ed. Ardent Media Inc, New York1998
          • Schwallie PC
          • Assenzo JR
          Contraceptive use: efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days.
          Fertil Steril. 1973; 24: 331-339
          • Said S
          • Omar K
          • Koetsawang S
          • Kiriwat O
          • Srisatayapan Y
          • Kazi A
          • et al.
          A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction.
          Contraception. 1986; 34: 223-236
          • The World Health Organization
          Multinational comparative clinical evaluation of two long acting injectable contraceptive steroids: norethisterone enanthate and medroxyporogesterone acetate. Final report.
          Contraception. 1983; 28: 1-20
          • The World Health Organization
          Improving access to quality care in family planning: medical eligibility criteria for contraceptive use.
          2nd ed. WHO, Geneva2001
          • Schwallie PC
          • Assenzo JR
          The effect of depomedroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review.
          Contraception. 1974; 10: 181-202
          • Petta CA
          • Faundes A
          • Dunson TR
          • Ramos M
          • DeLucio M
          • Faundes D
          • et al.
          Timing of onset of contraceptive effectiveness in Depo-Provera users: part I. changes in cervical mucus.
          Fertil Steril. 1998; 69: 252-257
          • Polaneczky M
          • Guarnaccia M
          Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
          Fam Plann Perspect. 1996; 28: 174-178
          • Betsey EM
          and Task Force on Long-Acting Systemic Agents for Fertility Regulation. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception.
          Adv Contracept. 1991; 7: 257-270
          • Said S
          • Omar K
          • Koetsawang S
          • Kiriwat O
          • Srisatayapan Y
          • Kazi A
          • et al.
          A multicentered phase III comparative clinical trial of depotmedroxy-progesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. the comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction.
          Contraception. 1987; 35: 591-610
          • Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer
          The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
          Int J Cancer. 1991; 49: 186-190
        2. Prentice A, Deary AJ, Bland A. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000; 2: CD002I22.

          • Vercellini P
          • Cortesi I
          • Crosignani PG
          Progestins for symptomatic endometriosis: a critical analysis of the evidence.
          Fertil Steril. 1997; 68: 368-393
          • Stones RW
          • Mountfield J
          Interventions for treating chronic pelvic pain in women (Cochrane Review).
          in: The Cochrane Library. Update Software, Oxford2003 (Issue 4)
          • Mattson RH
          • Cramer JA
          • Caldwell BV
          • Siconolfi BC
          Treatment of seizures with medroxyprogesterone acetate: preliminary report.
          Neurology. 1984; 34: 1255-1258
          • Gray RH
          Reduced risk of pelvic inflammatory disease with injectable contraceptives.
          Lancet. 1985; 1: 1046
          • Baeten JM
          • Nyange PM
          • Richardson BA
          • Lavreys L
          • Chohan B
          • Martin Jr, HL
          • et al.
          Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.
          Am J Obstet Gynecol. 2001; 185: 380-385
          • de Abood M
          • de Castillo Z
          • Guerrero F
          • Espino M
          • Austin KL
          Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients.
          Contraception. 1997; 56: 313-316
          • Sangi-Haghpeykar H
          • Poindexter 3rd, AN
          • Bateman L
          • Ditmore JR
          Experiences of injectable contraceptive users in an urban setting.
          Obstet Gynecol. 1996; 88: 227-233
          • Nelson A
          Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
          J Reprod Med. 1996; 41: 391-400
          • Moore LL
          • Valuck R
          • McDougall C
          • Fink W
          A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
          Contraception. 1995; 52: 215-219
          • Mainwaring R
          • Hales HA
          • Stevenson K
          • Hatasaka HH
          • Poulson AM
          • Jones KP
          • et al.
          Metabolic parameter, bleeding, and weight changes in U. S. women using progestin-only contraceptives.
          Contraception. 1995; 51: 149-153
          • Taneepanichskul S
          • Reinprayoon D
          • Jaisamrarn U
          Effects of DMPA on weight and blood pressure in long term acceptors.
          Contraception. 1999; 59: 301-303
          • Rees HD
          • Bonsall RW
          • Michael RP
          Pre-optic and hypothalamic neurons accumulate [3H]medroxyprogesterone acetate in male cynomolgus monkeys.
          Life Sei. 1986; 39: 1353-1359
          • Westhoff C
          • Truman C
          • Kalmuss D
          • Cushman L
          • Davidson A
          • Rulin M
          • et al.
          Depressive symptoms and depo-provera.
          Contraception. 1998; 57: 237-240
          • Gupta N
          • O’Brien RJacobsen LJ
          • Davis A
          • Zuckerman A
          • Supran S
          • et al.
          Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study.
          J Pediatr Adolesc Gynecol. 2001; 14: 71-76
          • Pardthaisong T
          Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis.
          J Biosoc Sci. 1984; 16: 23-34
          • Fotherby K
          • Howard G
          Return of fertility in women discontinuing injectable contraceptives.
          J Obstet Gynaecol. 1986; 6: 10-15
          • Perrotti M
          • Bahamondes L
          • Petta C
          • Castro S
          Forearm bone density in long term users of oral combined contraceptives and depot medroxyprogesteron acetate.
          Fertil Steril. 2001; 76: 469-474
          • Gbolade B
          • Ellis S
          • Murby B
          • Randall S
          • Kirkman R
          Bone density in long term users of depot medroxyprogesterone acetate.
          Br J Obstet Gynaecol. 1998; 105: 790-794
          • Cromer BA
          • Blair JM
          • Mahan JD
          • Zibners L
          • Naumovski Z
          A prospective comparison of bone density in adolescent girls receiving depo-medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
          J Pediatr. 1996; 129: 671-676
          • Cundy T
          • Cornish J
          • Roberts H
          • Elder H
          • Reid IR
          Spinal bone density in women using depot medroxyprogesterone contraception.
          Obstet Gynecol. 1998; 92: 569-573
          • Scholes D
          • Lacroix AZ
          • Ott SM
          • Ichikawa LE
          • Barlow WE
          Bone mineral density in women using depot medroxyprogesterone acetate for contraception.
          Obstet Gynecol. 1999; 93: 233-238
          • Berenson AB
          • Radecki CM
          • Grady JJ
          • Rickert VI
          • Thomas A
          A prospective, controlled study of the effects of hormonal contraception on bone mineral density.
          Obstet Gynecol. 2001; 98: 576-582
          • Scholes D
          • Lacroix AZ
          • Ichikawa LE
          • Barlow WE
          • Ott SM
          Injectable hormone contraception and bone density: results from a prospective study.
          Epidemiology. 2002; 13: 581-587
          • Busen NH
          • Britt RB
          • Rianon N
          Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years.
          J Adolesc Health. 2003; 32: 257-259
          • Orr-Walker BJ
          • Evans MC
          • Ames RW
          • Clearwater JM
          • Cundy T
          • Reid IR
          The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women.
          Clin Endocrinol. 1998; 49: 615-618
          • Petitti DB
          • Piaggio G
          • Mehta S
          • Cravioto MC
          • Meirik O
          Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health.
          Obstet Gynecol. 2000; 95: 736-744
          • Cundy T
          • Ames R
          • Home A
          • Clearwater J
          • Roberts H
          • Gamble G
          • et al.
          A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate.
          J Clin Endocrinol Metab. 2003; 88: 78-81
          • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multi-center, case-control study.
          Contraception. 1998; 57: 315-324
          • Vasilakis C
          • Jick H
          • del Mar Melero-Montes M
          Risk of idiopathic venous thromboembolism in users of progestagens alone.
          Lancet. 1999; 354: 1610-1611
          • Mishell Jr, DR
          Pharmacokinetics of depot medroxyprogesterone acetate contraception.
          J Reprod Med. 1996; 41: 381-390
          • Petta CA
          • Faundes A
          • Dunson TR
          • Ramos M
          • DeLucio M
          • Faundes D
          • et al.
          Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
          Fertil Steril. 1998; 70: 817-820
          • SOGC Committee Opinion
          Injectable medroxyprogesterone acetate for contraception. August.
          Policy statement no. 94. JSOGC. 2000; 22: 616-620
          • Pardthaisong T
          • Yenchit C
          • Gray R
          The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
          Contraception. 1992; 45: 313-324
          • Borgatta L
          • Murthy A
          • Chuang C
          • Beardsley L
          • Burnhill MS
          Pregnancies diagnosed during Depo-Provera use.
          Contraception. 2002; 66: 169-172
          • Hatcher RA
          • Schnare S
          Ask the experts: progestin-only contraceptives.
          Contracept Technol Update. 1993; 14: 114-115
          • Sheth A
          • Jain U
          • Sharma S
          • Adatia A
          • Patankar S
          • Andolsek L
          • et al.
          A randomized, double-blind study of two combined and two progestogen-only oral contraceptives.
          Contraception. 1982; 25: 243-252
          • Broome M
          • Fotherby K
          Clinical experience with the progestogen-only pill.
          Contraception. 1990; 42: 489-495
          • Perheentupa A
          • Critchley HO
          • lllingworth PJ
          • McNeilly AS
          Effect of progestin-only pill on pituitary-ovarian axis activity during lactation.
          Contraception. 2003; 67: 467-471
          • Moghissi KS
          • Syner FN
          • McBride LC
          Contraceptive mechanism of microdose norethindrone.
          Obstet Gynecol. 1973; 41: 585-594
          • Kesseru-Koos E
          Influence of various hormonal contraceptives on sperm migration in vivo.
          Fertil Steril. 1971; 22: 584-603
          • Landgren BM
          • Diczfalusy E
          Hormonal effects of the 300 meg norethis-terone minipill.
          Contraception. 1980; 21: 87-113
          • Moghissi KS
          • Marks C
          Effects of microdose progestogens on endogenous gonadotrophic and steroid hormones, cervical mucus properties, vaginal cytology and endometrium.
          Fertil Steril. 1971; 22: 424-434
          • Heinemann LA
          • Assmann A
          • DoMinh T
          • Garbe E
          Oral progestogen-only contraceptives and cardiovascular risk results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
          Eur J Contracept Reprod Health Care. 1999; 4: 67-73
          • Truitt ST
          • Frazer AB
          • Grimes DA
          • Gallo MF
          • Schulz KF
          Combined hormonal versus nonhormonal versus progestin-only contraception in lactation (Cochrane Review).
          in: The Cochrane Library. Update Software, Oxford2003 (Issue 4)
          • World Health Organization (WHO) Task Force on Oral Contraceptives
          Effects of hormonal contraceptives on breast milk composition and infant growth.
          Stud Farn Plann. 1988; 19: 361-369
          • Halderman LD
          • Nelson AL
          Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormon-al contraceptives on short-term breast-feeding patterns.
          Am J Obstet Gynecol. 2002; 186: 1250-1258
          • Tankeyoon M
          • Dusitsin N
          • Chalapati S
          • Koetsawang S
          • Saibiang S
          • Sas M
          • et al.
          Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task Force on Oral Contraceptives.
          Contraception. 1984; 30: 505-522
          • Guillebaud J
          Contraception: your questions answered. Pitman, New York NY1985
          • Cheng L
          • Zhu H
          • Wang A
          • Ren F
          • Chen J
          • Glasier A
          Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.
          Hum Reprod. 2000; 15: 1969-1972
          • Gemzell-Danielsson K
          • van Heusden AM
          • Killick SR
          • Croxatto HB
          • Bouchard P
          • Cameron S
          • et al.
          Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.
          Hum Reprod. 2002; 17: 2588-2593
          • The World Health Organization
          Improving access to quality care in family planning: medical eligibility criteria for contraceptive use.
          2nd ed. WHO, Geneva2001
        3. Wyeth-Ayerst comments on Norplant® system. Available on-line at <http//www.wyeth.com/news/Pressed_and_Released/pr08_17_2000.asp>. Web site updated August 17, 2000. Accessed January 20, 2004.

        4. Wyeth-Ayerst comment Back-up contraception no longer required for women using norplant system. Available on-line at <http//www.wyeth.com/news/Pressed_and_Released/pr07_26_2002.asp>. Web site updated July 26, 2002. Accessed January 20, 2004.

          • Sivin I
          • Mishell Jr, DR
          • Diaz S
          • Biswas A
          • Alvarez F
          • Darney P
          • et al.
          Prolonged effectiveness of Norplant capsule implants: a seven year study.
          Contraception. 2000; 61: 187-194
          • Gu S
          • Sivin I
          • Du M
          • Zhang L
          • Ying L
          • Meng F
          • et al.
          Effectiveness of Norplant implants through seven years: a large-scale study in China.
          Contraception. 1995; 52: 99-103
          • Meckstroth K
          • Darney P
          Implant contraception.
          Semin Reprod Med. 2001; 19: 339-354
          • Croxatto HB
          Progestin implants for female contraception.
          Contraception. 2002; 65: 15-19
          • Affandi B
          An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon.
          Contraception. 1998; 58: 99S-107S
          • Herjan J
          • Bennink TC
          Introduction: presentation of clinical data on implanon.
          Contraception. 1998; 58: 75S-77S
          • Kennedy H
          • Murnaghan M
          Implanon: when is the ideal time to insert?.
          J Farn Plann Reprod Health Care. 2001; 27: 158
          • Sivin I
          • Mishell D
          • Darney P
          • Wan L
          • Christ M
          Levonorgestrel capsule implants in the United States: a 5 year study.
          Obstet Gynecol. 1998; 92: 337-344
          • Sivin I
          • Alvarez F
          • Mishell Jr, DR
          • Darney P
          • Wan L
          • Brache V
          • et al.
          Contraception with two levonorgestrel rod implants: a 5-year study in the United States and Dominican Republic.
          Contraception. 1998; 58: 275-282

        References

          • Jordan WM
          Pulmonary embolism.
          Lancet. 1961; 2: 1146-1147
          • Lidegaard O
          Oral contraceptives and venous thromboembolism: an epidemiological review.
          Eur J Contracept Reprod Health Care. 1996; 1: 13-20
          • Williams JK
          Evidence-based medicine and contraception.
          Obstet Gynecol Clin North Am. 2000; 27: 683-693
          • Anderson Jr, FA
          • Wheeler HB
          • Goldberg RJ
          • Hosmer DW
          • Patwardhan NA
          • Jovanovic B
          • et al.
          A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.
          Arch Intern Med. 1991; 151: 933-938
          • Farley TMM
          • Collins J
          • Schlesselman JJ
          Hormonal contraception and risk of cardiovascular disease: an international perspective.
          Contraception. 1998; 57: 211-230
          • White RH
          The epidemiology of venous thromboembolism.
          Circulation. 2003; 107: 14-18
          • Lindqvist P
          • Dahlback B
          • Marsal K
          Thrombotic risk during pregnancy: a population study.
          Obstet Gynecol. 1999; 94: 595-599
          • Douketis JD
          • Kearon C
          • Bates S
          • Duku EK
          • Ginsberg JS
          Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.
          JAMA. 1998; 279: 458-462
          • Vandenbroucke JP
          • Rosing J
          • Bloemenkamp KWM
          • Middeldorp S
          • Heimerhorst FM
          • Bouma BN
          • et al.
          Oral contraceptives and the risk of venous thrombosis.
          N Engl J Med. 2001; 344: 1527-1535
          • Lidegaard O
          • Edstrom B
          • Kreiner S
          Oral contraceptives and venous thromboembolis: a case-control study.
          Contraception. 1998; 57: 291-301
          • Bloemenkamp KWM
          • Rosendaal FR
          • Heimerhorst FM
          • Vandenbroucke JR
          Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.
          Arch Intern Med. 2000; 160: 49-52
          • Crosignani PG
          • La Vecchia C
          on behalf of the ESHRE Capri Workshop Group. Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy.
          Hum Reprod Update. 1999; 5: 681-687
          • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.
          Lancet. 1995; 346: 1575-1582
          • Farmer RDT
          • Lawrenson RA
          • Todd JC
          • Williams TJ
          • MacRae KD
          • Tyrer F
          • et al.
          A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
          Br J Clin Pharmacol. 2000; 49: 580-590
          • Rosendaal FR
          • Heimerhorst FM
          • Vandenbroucke JP
          Female hormones and thrombosis.
          Arterioscler ThrombVasc Biol. 2002; 22: 201-210
          • Jick H
          • Jick SS
          • Gurewich V
          • Myers MW
          • Vasilakis C
          Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
          Lancet. 1995; 346: 1589-1593
          • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease.
          Lancet. 1995; 346: 1582-1588
          • Lewis MA
          • Heinemann LAJ
          • MacRae KD
          • Bruppacher R
          • Spitzer WO
          with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research.
          Contraception. 1996; 54: 5-13
          • Lewis MA
          The transnational study on oral contraceptives and the health of young women: methods, results, new analyses and the healthy user effect.
          Hum Reprod Update. 1999; 5: 707-720
          • Kemmeren JM
          • Algra A
          • Grobbee DE
          Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.
          BMJ. 2001; 323: 1-9
          • Vasilakis-Scaramozza C
          • Jick H
          Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
          Lancet. 2001; 358: 1427-1429
          • Lidegaard O
          Absolute and Attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethynilestradiol.
          J Obstet Gynaecol Can. 2003; 25: 575-577
          • Spitzer WO
          Cyproterone acetate with Ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
          J Obstet Gynaecol Can. 2003; 25: 1011-1018
          • Seaman HE
          • de Vries CS
          • Farmer RDT
          The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
          Hum Reprod. 2003; 18: 522-526
          • Vandenbroucke JP
          • Koster T
          • Briet E
          • Reitsma PH
          • Bertina RM
          • Rosendaal FR
          Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
          Lancet. 1994; 344: 1453-1457
          • Seligsohn U
          • Lubetsky A
          Genetic susceptibility to venous thrombosis.
          N Engl J Med. 2001; 344: 1222-1231
          • Vandenbroucke JP
          • van der Meer FJM
          • Heimerhorst FM
          • Rosendaal FR
          • Leiden Factor V
          should we screen oral contraceptive users and pregnant women?.
          BMJ. 1996; 313: 1127-1130
          • Prandoni P
          • Lensing AWA
          • Cogo A
          • Cuppini S
          • Villalta S
          • Carta M
          • Cattelan AM
          • Polistena P
          • Bernardi E
          • Prins MH
          The long-term clinical course of acute deep venous thrombosis.
          Ann Intern Med. 1996; 125: 1-7
          • de Bruijn SFTM
          • Stam J
          • Koopman MMW
          • Vandenbroucke JP
          for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions.
          BMJ. 1998; 316: 589-592
          • Dunn NR
          • Arscott A
          • Thorogood M
          • Faragher B
          • de Caestecker L
          • Mac-Donald TM
          • et al.
          Regional variation in incidence and case fatality of myocardial infarction among young women in England, Scotland and Wales.
          J Epidemiol Community Health. 2000; 54: 293-298
          • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study.
          Lancet. 1997; 349: 1202-1209
          • Farley TMM
          • Meirik O
          • Chang CL
          • Poulter NR
          Combined oral contraceptives, smoking, and cardiovascular risk.
          J Epidemiol Community Health. 1998; 52: 775-785
          • Sidney S
          • Petitti DB
          • Quesenberry Jr, CP
          • Klatsky AL
          • Ziel HK
          • Wolf S
          Myocardial infarction in users of low-dose oral contraceptives.
          Obstet Gynecol. 1996; 88: 939-944
          • Sidney S
          • Siscovick DS
          • Petitti DB
          • Schwartz SM
          • Quesenberry CP
          • Psaty BM
          • et al.
          Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies.
          Circulation. 1998; 98: 1058-1063
          • Rosenberg L
          • Palmer JR
          • Rao RS
          • Shapiro S
          Low-dose oral contraceptive use and the risk of myocardial infarction.
          Arch Intern Med. 2001; 161: 1065-1070
          • Dunn N
          • Thorogood M
          • Faragher B
          • de Caestecker L
          • MacDonald TM
          • McCollum C
          • et al.
          Oral contraceptives and myocardial infarction: results of the MICA case-control study.
          BMJ. 1999; 318: 1579-1583
          • Tanis BC
          • van den Bosch MAAJ
          • Kemmeren JM
          • Cats VM
          • Heimerhorst FM
          • Algra A
          • et al.
          Oral contraceptives and the risk of myocardial infarction.
          N Engl J Med. 2001; 345: 1787-1793
          • Lewis MA
          • Heinemann LAJ
          • Spitzer WO
          • MacRae KD
          • Bruppacher R
          for the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women.
          Contraception. 1997; 56: 129-140
          • Dunn NR
          • Arscott A
          • Thorogood M
          The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study.
          Contraception. 2001; 63: 65-69
          • Spitzer WO
          • Faith JM
          • MacRae KD
          Myocardial infarction and third generation oral contraceptives: aggregation of recent studies.
          Hum Reprod. 2002; 17: 2307-2314
          • Lidegaard O
          Thrombotic diseases in young women and the influence of oral contraceptives.
          Am J Obstet Gynecol. 1998; 179: 62-67
          • Lewis MA
          Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?.
          Am J Obstet Gynecol. 1998; 179: S68-77
          • Lubianca JN
          • Faccin CS
          • Fuchs FD
          Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women.
          Contraception. 2003; 67: 19-24
          • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
          Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study.
          Lancet. 1996; 348: 498-505
          • Petitti DB
          • Sidney S
          • Bernstein A
          • Wolf S
          • Quesenberry C
          • Ziel HK
          Stroke in users of low-dose oral contraceptives.
          N Engl J Med. 1996; 335: 8-15
          • Schwartz SM
          • Siscovick DS
          • Longstreth Jr, WT
          • Psaty BM
          • Beverly RK
          • Raghunathan TE
          • et al.
          Use of low-dose oral contraceptives and stroke in young women.
          Ann Intern Med. 1997; 127: 596-603
          • Lidegaard O
          Oral contraception and risk of a cerebral thromboembolic attack results of a case-control study.
          BMJ. 1993; 306: 956-963
          • Heinemann LAJ
          • Lewis MA
          • Spitzer WO
          • Thorogood M
          • Guggenmoos-Holzmann I
          • Bruppacher R
          and the Transnational Research Group on Oral Contraceptives and the Health of Young Wbmen. Thromboembolic stroke in young women: a European case-control study on oral contraceptives.
          Contraception. 1998; 57: 29-37
          • Kemmeren JM
          • Tanis BC
          • van den Bosch MAAJ
          • Bollen ELEM
          • Heimerhorst FM
          • van der Graaf Y
          • et al.
          Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.
          Stroke. 2002; 33: 1202-1208
          • Gillum LA
          • Mamidipudi SK
          • Johnston SC
          Ischemic stroke risk with oral contraceptives: a meta-analysis.
          JAMA. 2000; 284: 72-78
          • Poulter NR
          • Chang CL
          • Farley TMM
          • Marmot MG
          • Meirik O
          and the WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives.
          Lancet. 1999; 354: 301-304
          • Lidegaard O
          • Kreiner S
          Contraceptives and cerebral thrombosis: a five-year national case-control study.
          Contraception. 2002; 65: 197-205
          • Goldstein LB
          • Adams R
          • Becker K
          • Furberg CD
          • Gorelick PB
          • Hademenos G
          • et al.
          Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association.
          Circulation. 2001; 103: 163-182
          • Curtis KM
          • Chrisman CE
          • Peterson HB
          for the WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances.
          Obstet Gynecol. 2002; 99: 1100-1112
          • Tzourio C
          • Tehindrazanarivelo A
          • Iglesias S
          • Alperovitch A
          • Chedru F
          • d’Anglejan-Chatillon J
          • et al.
          Case-control study of migraine and risk of ischaemic stroke in young women.
          BMJ. 1995; 310: 830-833
          • Chang CL
          • Donaghy M
          • Poulter N
          and World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study.
          BMJ. 1999; 318: 13-18
          • Donaghy M
          • Chang CL
          • Poulter N
          on behalf of the European Collaborators of the World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age.
          J Neurol Neurosurg Psychiatry. 2002; 73: 747-750
          • Bousser MG
          • Conard J
          • Kittner S
          • de Lignières B
          • MacGregor EA
          • Massiou H
          • et al.
          Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine.
          Cephalalgia. 2000; 20 (The International Headache Society Task Force on Combined Oral Contraceptives and Hormone Replacement Therapy): 155-156
          • Becker WJ
          Migraine and oral contraceptives.
          Can J Neurol Sci. 1997; 24: 16-21
          • Farley TMM
          • Meirik O
          • Collins J
          Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks.
          Hum Reprod Update. 1999; 5: 721-735
          • Vasilakis C
          • Jick H
          del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone.
          Lancet. 1999; 354: 1610-1611
          • Heinemann LAJ
          • Assmann A
          • DoMinh T
          • Garbe E
          and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Oral progestogen-only contraceptives and cardiovascular risk results from the Transnational Study on Oral Contraceptives and the Health ofYoung Women.
          Eur J Contracept Reprod Health Care. 1999; 4: 67-73
          • Poulter ND
          • Chang CL
          • Farley TMM
          • Meirik O
          Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.
          Lancet. 1999; 354: 1610
          • Parker WA
          Estrogen-induced pancreatitis.
          Clin Pharm. 1983; 2: 75-79
          • Skouby SO
          • Molsted-Pedersen L
          • Kuhl C
          • Bennet P
          Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
          Fertil Steril. 1986; 46: 858-864
          • Kjos SL
          Contraception in diabetic women.
          Obstet Gynecol Clin North Am. 1996; 23: 243-258
          • Garg SK
          • Chase HR Marshall G
          • Hoops SL
          • Holmes DL
          • Jackson WE
          Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus.
          JAMA. 1994; 271: 1099-1102
          • Bennion LJ
          • Ginsberg RL
          • Garnick MB
          • Bennett PH
          Effects of oral contraceptives on the gallbladder bile of normal women.
          N Engl J Med. 1976; 294: 189-192
          • Grodstein F
          • Colditz GA
          • Hunter DJ
          • Manson JE
          • Willett WC
          • Stampfer MJ
          A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors.
          Obstet Gynecol. 1994; 84: 207-214
          • Connolly TJ
          • Zuckerman AL
          Contraception in the patient with liver disease.
          Semin Perinatol. 1998; 22: 178-182
          • Godet PG
          • May GR
          • Sutherland LR
          Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease.
          Gut. 1995; 37: 668-673
          • Cosnes J
          • Carbonnel F
          • Carrat F
          • Beaugerie L
          • Gendre JR
          Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study.
          Gut. 1999; 45: 218-222
          • Timmer A
          • Sutherland LR
          • Martin F
          and The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease.
          Gastroenterology. 1998; 114: 1143-1150
          • Hanker JR
          Gastrointestinal disease and oral contraception.
          Am J Obstet Gynecol. 1990; 163: 2204-2207
          • Mok CC
          • Lau CS
          • Wong RW
          Use of exogenous estrogens in systemic lupus erythematosus.
          Semin Arthritis Rheum. 2001; 30: 426-435
          • Prengler M
          • Pavlakis SG
          • Prohovnik I
          • Adams RJ
          Sickle cell disease: the neurological complications.
          Ann Neurol. 2002; 51: 543-552
          • de Abood M
          • de Castillo Z
          • Guerrero F
          • Espino M
          • Austin KL
          Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients.
          Contraception. 1997; 56: 313-316
          • Yoong WC
          • Tuck SM
          Menstrual pattern in women with sickle cell anaemia and its association with sickling crises.
          J Obstet Gynaecol Can. 2002; 22: 399-401
          • Vessey M
          • Painter R
          • Yeates D
          Oral contraception and epilepsy: findings in a large cohort study.
          Contraception. 2002; 66: 77-79
          • Patsalos PN
          • Froscher W
          • Pisani F
          • van Rijn CM
          The importance of drug interactions in epilepsy therapy.
          Epilepsia. 2002; 43: 365-385
          • Crawford P
          Interactions between antiepileptic drugs and hormonal contraception.
          CNS Drugs. 2002; 16: 263-272
          • Oakes J
          • Hahn PM
          • Lillicrap D
          • Reid RL
          A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.
          Am J Obstet Gynecol. 2002; 187: 1539-1543

        References

          • Andersson K
          • Odlind V
          • Rybo G
          Levonorgestrel-releasing and copper-releasing (Nova-T) lUDs during five years of use: a randomized comparative trial.
          Contraception. 1994; 49: 56-72
        1. No author. The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3, 5 and 7 years of use-results from three randomized multicentre trials. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on the Safety and Efficacy of Fertility Regulating Methods. Contraception 1990; 42: 141-58.

          • Videlo-Rivero L
          • Etchepareborda JJ
          • Kesseru E
          Early chorionic activity in women bearing inert IUD, copper IUD, and levonorgestrel releasing IUD.
          Contraception. 1987; 36: 217-226
          • Stanford J
          • Mikolajczyk R
          Mechanisms of action of intrauterine devices: Update and estimation of postfertilization effects.
          Am J Obstet Gynecol. 2002; 187: 1699-1708
          • Sivin I
          IUDs are contraceptives, not abortifacients: a comment on research and belief.
          Stud Farn Plann. 1989; 20: 355-359
          • Ortiz ME
          • Croxatto HB
          • Bardin CW
          Mechanisms of action in intrauterine devices.
          Obstet Gynecol Surv. 1996; 51: S42-S51
          • Wilcox AJ
          • Weinberg CR
          • Armstrong EG
          • Canfield RE
          Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay.
          Fertil Steril. 1987; 47: 265-269
          • Critchley HO
          • Wang HJones RL
          • Kelly RW
          • Drudy TA
          • Gebbie AE
          • et al.
          Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
          Hum Reprod. 1998; 13: 1218-1224
          • Zhu P
          • Liu X
          • Luo H
          • Gu Z
          • Cheng J
          • Xu R
          • et al.
          The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use.
          Hum Reprod. 1999; 14: 970-975
          • Jonsson B
          • Landgren B
          • Eneroth R
          Effects of various IUDs on the composition of cervical mucus.
          Contraception. 1991; 43: 447-458
          • Nilsson CG
          • Lahteenmaki PL
          • Luukkainen T
          Ovarian function in amenor-rheic and menstruating users of a levonorgestrel-releasing device.
          Fertil Steril. 1984; 41: 52-55
          • Barbosa I
          • Bakos O
          • Olsson SE
          • Odlind V
          • Johansson ED
          Ovarian function during use of a levonorgestrel-releasing IUD.
          Contraception. 1990; 42: 51-66
          • The World Health Organization
          Improving access to quality care in family planning: medical eligibility criteria for contraceptive use.
          2ed ed. WHO, Geneva2001
          • Benshushan A
          • Paltiel O
          • Rojansky N
          • Brzezinski A
          • Laufer N
          IUD use and the risk of endometrial cancer.
          Eur J Obstet Gynecol. 2002; 105: 166-169
          • Andersson JK
          • Rybo G
          Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia.
          Br J Obstet Gynaecol. 1990; 97: 690-694
          • Barrington JW
          • Bowens-Simpkins R
          The levonorgestrel intrauterine system in the management of menorrhagia.
          Br J Obstet Gynaecol. 1997; 104: 614-616
          • Irvine GA
          • Campbell-Brown MB
          • Lumsden MA
          • Heikkila A
          • Walker JJ
          • Cameron IT
          Randomized comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
          Br J Obstet Gynaecol. 1998; 105: 592-598
          • Istre O
          • Trolle B
          Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection.
          Fertil Steril. 2001; 76: 304-309
          • Lethaby AE
          • Cooke I
          • Rees M
          Progesterone/progestogen releasing intrauterine systems for heavy menstrual bleeding (Cochrane Methodology Review).
          in: The Cochrane Library. 2003 (Issue 4)
          • Ronnerdag M
          • Odlind V
          Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use.
          Acta Obstet Gynecol Scand. 1999; 78: 716-721
          • Lahteenmaki P
          • Haukkamaa M
          • Puolakka J
          • Riikonen U
          • Sainio S
          • Suvisaari J
          • et al.
          Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy.
          BMJ. 1998; 316: 1122-1126
          • Hurskainen R
          • Teperi J
          • Rissanen P
          • Aalto AM
          • Grenman S
          • Kivela A
          • et al.
          Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial.
          Lancet. 2001; 357: 273-277
          • Pakarinen RToivonen J
          • Luukkainen T
          Therapeutic use of the LNG IUS, and counseling.
          Semin Reprod Med. 2001; 19: 365-372
          • Gardner FJ
          • Konje JC
          • Abrams KR
          • Brown LJ
          • Khanna S
          • Al-Azzawi F
          • et al.
          Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
          Lancet. 2000; 356: 1698-1699
          • Fong YF
          • Singh K
          Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient.
          Contraception. 1999; 60: 51-53
          • Starczewski A
          • Iwanicki M
          Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids.
          Ginekol Pol. 2000; 71: 1221-1225
          • Milsom I
          • Andersson K
          • Jonasson K
          • Lindstedt G
          • Rybo G
          The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status.
          Contraception. 1995; 52: 175-179
          • Larsson G
          • Milsom I
          • Jonasson K
          • Lindstedt G
          • Rybo G
          The long-term effects of copper surface area on menstrual blood loss and iron status in women fitted with an IUD.
          Contraception. 1993; 48: 471-480
          • Luukkainen T
          • Allonen H
          • Haukkamaa M
          • Holma P
          • Pyorala T
          • Terho J
          • et al.
          Effective contraception with levonorgestrel-releasing intrauterine device: 12 month report of a European multinational study.
          Contraception. 1987; 36: 169-179
          • Backman T
          • Huhtala S
          • Luoto R
          • Tuominen J
          • Rauramo I
          • Koskenvuo M
          Advance information improves user satisfaction with the levonorgestrel intrauterine system.
          Obstet Gynecol. 2002; 99: 608-613
          • Jarvela I
          • Tekay A
          • Jouppila R
          The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women.
          Hum Reprod. 1998; 13: 3379-3383
          • Pakarinen PI
          • Suvisaari J
          • Luukkainen T
          • Lahteenmaki P
          Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
          Fertil Steril. 1997; 68: 59-64
          • The World Health Organization
          Mechanism of action, safety, and efficacy of intrauterine devices. WHO, Geneva1987 (Technical Report Series, 753.)
          • Harrison-Woolrych M
          • Ashton J
          • Coulter D
          Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported?.
          Contraception. 2003; 67: 53-56
          • Tietze C
          Evaluation of intrauterine devices: ninth progress report of the Cooperative Statistical Program.
          Stud Farn Plann. 1970; 55: 1-40
          • Lee NC
          • Rubin GL
          • Ory HW
          • Burkman RT
          Type of intrauterine device and the risk of pelvic inflammatory disease.
          Obstet Gynecol. 1983; 62: 1-6
          • Farley TM
          • Rosenberg MJ
          • Rowe PJ
          • Chen JH
          • Meirik O
          Intrauterine devices and pelvic inflammatory disease: an international perspective.
          Lancet. 1992; 339: 785-788
          • Toivonen J
          • Luukkainen T
          • Allonen H
          Protective effect of intrauterine release of levonorgestrel on pelvic infections: three years’ comparative experience of levonorgestrel and copper-releasing intrauterine devices.
          Obstet Gynecol. 1991; 77: 261-264
          • Sivin I
          • Stern J
          • Coutinho E
          • Mattos CE
          • el Mahgoub S
          • Diaz S
          • et al.
          Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 meg/day (LNg 20) and the copper T380 Ag IUD.
          Contraception. 1991; 44: 473-480
          • Bahamondes L
          • Diaz J
          • Marchi NM
          • Petta CA
          • Cristofoletti ML
          • Gomez G
          Performance of copper intrauterine devices when inserted after an expulsion.
          Hum Reprod. 1995; 10: 2917-2918
          • Zhang J
          • Feldblum PJ
          • Chi IC
          • Farr MG
          Risk factors for copper-T IUD expulsion: an epidemiological analysis.
          Contraception. 1992; 46: 427-433
          • United Kingdom Family Planning Research Network
          Pregnancy outcome associated with the use of IUDs.
          Br J Farn Plann. 1989; 15: 7-10
          • Chaim W
          • Mazor M
          Pregnancy with an intrauterine device in situ and preterm delivery.
          Arch Gynecol Obstet. 1992; 252: 21-24
          • Hubacher D
          • Lara-Ricalde R
          • Taylor DJ
          • Guerra-Infante F
          • Guzman-Rodriguez R
          Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women.
          N Engl J Med. 2001; 345: 561-567
          • Grimes DA
          Intrauterine devices and infertility: sifting through the evidence.
          Lancet. 2001 Jul 7; 358: 6-7
          • Jovanovic R
          • Barone CM
          • Van Natta FC
          • Congema E
          Preventing infection related to insertion of an intrauterine device.
          J Reprod Med. 1988; 33: 347-352
          • Peterson HB
          • Xia Z
          • Hughes JM
          • Wilcox LS
          • Tylor LR
          • Trussell J
          The risk of pregnancy after tubal sterilization: findings from the U. S. Collabora tive Review of Sterilization.
          Am J Obstet Gynecol. 1996 Apr; 174: 1161-1168
          • Sturridge F
          • Guillebaud J
          A Risk-Benefit Assessment of the Levono-rgestrel-Releasing Intrauterine System.
          Drug Safety. 1996; 15: 430-440
          • White MK
          • Ory HW
          • Rooks JB
          • Rochat RW
          Intrauterine device termination rates and the menstrual cycle day of insertion.
          Obstet Gynecol. 1980; 55: 220-224
          • Grimes D
          • Schulz K
          • van Vliet H
          • Stanwood N
          Immediate post-partum insertion of intrauterine devices (Cochrane Methodology Review).
          in: The Cochrane Library. 2003 (4)
          • Grimes DA
          • Schulz KF
          Antibiotic prophylaxis for intrauterine contraceptive device insertion (Cochrane Methodology Review).
          in: The Cochrane Library. 2001 (2)
          • Dajani AS
          • Taubert KA
          • Wilson W
          • Bolger AF
          • Bayer A
          • Ferrieri P
          • et al.
          Prevention of bacterial endocarditis: recommendations by the American Heart Association.
          JAMA. 1997; 277: 1794-1801
          • Assaf A
          • Gohar M
          • Saad S
          • el-Nashar A
          • Abdel Aziz A
          Removal of intrauterine devices with missing tails during early pregnancy.
          Contraception. 1992; 45: 541-546
          • Hucke J
          • Campo RL
          • Kozlowski P
          • De Bruyne F
          Experience with hysteroscopy or ultrasound-controlled removal of an intrauterine spiral with no visible thread in early pregnancy.
          Geburtshilfe Frauenheilkd. 1991; 51: 31-33
          • Lippes J
          Pelvic actinomycosis: a review and preliminary look at prevalence.
          Am J Obstet Gynecol. 1999; 180: 265-269
          • Merki-Feld GS
          • Lebeda E
          • Hogg B
          • Keller PJ
          The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper-and levonorgestrel-releasing intrauterine devices.
          Contraception. 2000; 61: 365-368